Generic Drug Market Faces Steepest Tariff Threat as Trump Announces Phased Duties Targeting US Reshoring

Generic Drug Market Faces Steepest Tariff Threat as Trump Announces Phased Duties Targeting US Reshoring​

US President Donald Trump has unveiled a drastic new tariff regime targeting generic medicine imports into the United States. The policy dictates a staged increase in duties over several years, aimed at pressuring pharmaceutical companies to shift manufacturing back to American soil. This move marks a significant escalation in the administration's sustained push for greater domestic drug production and reduced reliance on overseas supply chains.

The proposed tariff timeline is highly aggressive. Generic drugs will initially enjoy zero per cent duty from August 1, 2026, through two years thereafter. The import duty is then set to sharply rise to 100 per cent in August 2028, with the rate doubling again to 200 per cent starting from August 2029.

Targeting Reshoring Through Penalty Mechanism​

In a post released on his Truth Social platform, the US President stated that the plan is designed "in order to RESHORE Generic Pharmaceutical Production into America." He emphasized that companies failing to establish manufacturing capacity within the given timeframe would face these increasing penalties.

The administration has repeatedly argued that protecting the country's drug supply requires bolstering domestic production capabilities. While generic drugs face this intense pressure, Trump clarified that his existing policy regarding patented and innovative medicines remains unchanged. He claimed that pharmaceutical investment in US facilities is accelerating rapidly.

Impact on Generic Manufacturers and Global Supply Chains​

The announcement poses a unique and substantial challenge to the global network of generic drug manufacturers. These firms typically operate on significantly narrower margins compared to those creating patented medicines, making them highly vulnerable to sharp increases in import costs.

Unlike large pharmaceutical companies producing innovative drugs who may have room to absorb higher costs, generic manufacturers rely heavily on international supply chains to maintain affordable pricing for consumers. Richard Saynor, CEO of Swiss generic drugmaker Sandoz Group AG, previously warned that the threat of such steep US tariffs could restrict patient access and drive up medicine prices.

Consequences for India's Pharmaceutical Exports​

The proposed tariff regime carries major potential consequences for India, which stands as the world's largest exporter of generic medicines to the American market. This issue is acutely important as US healthcare providers depend heavily on affordable Indian generics.

Data cited by Bloomberg from India's Commerce Ministry indicated that pharmaceutical exports from India to the US amounted to $10.5 billion in 2024-25, making drugs one of three key export categories for the country. A broad tariff could jeopardize a significant portion of these crucial exports.

Mitigation and Regulatory Context​

While the specifics of Indian pharmaceutical exports under this latest plan remain unclear, an earlier trade agreement between India and the US did include provisions allowing India to "receive negotiated outcomes" regarding generic pharmaceuticals and ingredients. This potentially allows for exemptions or separate tariff arrangements.

The move follows previous regulatory action by the administration in April 2025, when a Section 232 investigation was launched into pharmaceutical imports under the Trade Expansion Act, which could have opened pathways for tariffs on non-US medicines. The White House has previously used the threat of steep future duties and delayed implementation dates as a negotiating tactic in its broader trade policy overhaul.